home / stock / bmed / bmed news


BMED News and Press, BLACKROCK ETF TRUS From 12/09/21

Stock Information

Company Name: BLACKROCK ETF TRUS
Stock Symbol: BMED
Market: NYSE

Menu

BMED BMED Quote BMED Short BMED News BMED Articles BMED Message Board
Get BMED Alerts

News, Short Squeeze, Breakout and More Instantly...

BMED - What's Driving Small-Cap Returns?

While inflation was at first believed to be transitory, it is now beginning to look persistent. Biotech stocks are close to 6.5% of the Russell 2000 Value Index benchmark, and only a few have earnings and positive cash flows. We also think the outlook is rosy for small-cap value i...

BMED - Using Biotechnology Stocks To Help Navigate The Ongoing COVID Crisis

With each new outbreak and variant, comes new fears, government lockdowns and hopes for recovery through science and medicine in the form of effective vaccines. Until recently, investor mindsets had shifted to a “living with COVID-19” mentality, supported by abundant sti...

BMED - U.S. Consumer Goods Producers Report Highest Capacity Constraints

The latest IHS Markit US Sector PMI revealed that six of the seven broad sectors tracked by the surveys reported higher output in November. Despite some of the supply chain problems having eased in November, the extent to which production growth had been constrained is consistent with...

BMED - Healthcare: The Best Defense Is A Good Offense

We are particularly enthused about a broad area that falls within the life science tools and services category, where we find many companies that are enabling innovative breakthroughs. Other growth themes in healthcare have either arisen or accelerated due to the COVID-19 pandemic. Th...

BMED - U.S. Drug Price Regulation: Overhang To Persist

In making the case for less stringent regulations, pharmaceutical companies highlight the distinctions between list prices and net prices. The industry projects potential negative implications for patient access and R&D investments, and support in Congress has historically be limi...

BMED - Bet On Biopharma - Data, Digitization And Discovery

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....

BMED - Changes In Q3 '21 Expected Revenue Growth Rates For S&P 500

Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...

BMED - Delta Wave Hits Hospitality, Autos, Tech And Construction, Boosts Healthcare

Price pressures are most concentrated in those sectors reporting the greatest constraints. Output consequently fell in China as well as a number of other smaller Asia-Pacific economies, and growth slowed in the US and Europe. The constraints on production caused by a lack of input...

BMED - Earnings Bounce Poses Quality Test For Equity Investors

As the world convalesced from the pandemic, stocks advanced in the second quarter and earnings rebounded across sectors. With business gains broadening amid complex market risks, we think investors should lean on quality to find stocks that will perform well in a normalizing world eco...

BMED - Weekly Market Pulse: Contrasts And Contradictions

As we mark the halfway point of the year, the economy is in full recovery mode and asset prices are soaring. As we enter the second half of the year though, it is hard to ignore some contradictions. Economic growth in H1 is going to print a big number, and yet, the 10-year Treasury no...

Previous 10 Next 10